Reputation Institute (RI), provider of reputation measurement, monitoring, and management services, announced its annual US Pharma RepTrak rankings. The survey looks at 2,608 individual ratings of pharma companies for the first quarter of 2018 and quantifies the emotional bond stakeholders have with pharma companies in the US, and how these connections drive supportive behavior such as the willingness to purchase a company’s products, recommend the brand, invest in or work for a company.
The top 10 companies in RI’s 2018 US Pharma RepTrak are:
1. Sanofi
2. Genentech
3. Celgene
4. AbbVie
5. Biogen
6. Bayer
7. Gilead
8. Allergan
9. Novo Nordisk
10. McKesson
The 2018 US Pharma RepTrak results reveal that national and industry reputations are under stress, with pharmaceutical companies following the broader national trends with a -3.7 point decline in reputation score compared to 2017. RI’s research analyst, Meghan Burke, wrote about this in detail for Pharm Exec’s blog. See her blog post here.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.